{"count": 4, "results": [{"_id": "32132864", "pmid": 32132864, "pmcid": "PMC7053347", "title": "Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events", "journal": "Int J Med Sci", "authors": ["Kinoshita S", "Hosomi K", "Yokoyama S", "Takada M"], "date": "2020-01-16T00:00:00Z", "doi": "10.7150/ijms.39342", "meta_date_publication": "2020", "meta_volume": "17", "meta_issue": "3", "meta_pages": "302-309", "score": 50288.5, "text_hl": "Furthermore, the significant inverse association between @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and @<m>DISEASE_Lung_Diseases_Interstitial</m> @DISEASE_MESH:D017563 @@@interstitial lung disease@@@, suggesting that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ might mitigate the risk of @<m>DISEASE_Lung_Diseases_Interstitial</m> @DISEASE_MESH:D017563 @@@interstitial lung disease@@@, warrants further scrutiny. ", "citations": {"NLM": "Kinoshita S, Hosomi K, Yokoyama S, Takada M. Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events Int J Med Sci. 2020;17(3):302-309. PMID: 32132864", "BibTeX": "@article{32132864, title={Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events}, author={Kinoshita S and Hosomi K and Yokoyama S and Takada M}, journal={Int J Med Sci}, volume={17}, number={3}, pages={302-309}}"}}, {"_id": "37261145", "pmid": 37261145, "pmcid": "PMC10228833", "title": "Metformin-Induced Eosinophilic Interstitial Lung Disease", "journal": "Cureus", "authors": ["Alyami SM", "Alrasheed SK", "Albogami BA"], "date": "2023-04-30T00:00:00Z", "doi": "10.7759/cureus.38339", "meta_date_publication": "2023 Apr", "meta_volume": "15", "meta_issue": "4", "meta_pages": "e38339", "score": 50277.8, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@-Induced @<m>DISEASE_Lung_Diseases_Interstitial</m> @DISEASE_MESH:D017563 @@@Eosinophilic Interstitial Lung Disease@@@", "citations": {"NLM": "Alyami SM, Alrasheed SK, Albogami BA. Metformin-Induced Eosinophilic Interstitial Lung Disease Cureus. 2023 Apr;15(4):e38339. PMID: 37261145", "BibTeX": "@article{37261145, title={Metformin-Induced Eosinophilic Interstitial Lung Disease}, author={Alyami SM and Alrasheed SK and Albogami BA}, journal={Cureus}, volume={15}, number={4}, pages={e38339}}"}}, {"_id": "25078646", "pmid": 25078646, "title": "Metformin/glibenclamide-related interstitial lung disease: a case report.", "journal": "Sarcoidosis Vasc Diffuse Lung Dis", "authors": ["Zuccarini G", "Bocchino M", "Assante LR", "Rea G", "Sanduzzi A"], "date": "2014-07-08T00:00:00Z", "meta_date_publication": "2014 Jul 8", "meta_volume": "31", "meta_issue": "2", "meta_pages": "170-3", "score": 50068.047, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@/@CHEMICAL_Glyburide @CHEMICAL_MESH:D005905 @@@glibenclamide@@@-related @<m>DISEASE_Lung_Diseases_Interstitial</m> @DISEASE_MESH:D017563 @@@interstitial lung disease@@@: a case report.", "citations": {"NLM": "Zuccarini G, Bocchino M, Assante LR, Rea G, Sanduzzi A. Metformin/glibenclamide-related interstitial lung disease: a case report. Sarcoidosis Vasc Diffuse Lung Dis. 2014 Jul 8;31(2):170-3. PMID: 25078646", "BibTeX": "@article{25078646, title={Metformin/glibenclamide-related interstitial lung disease: a case report.}, author={Zuccarini G and Bocchino M and Assante LR and Rea G and Sanduzzi A}, journal={Sarcoidosis Vasc Diffuse Lung Dis}, volume={31}, number={2}, pages={170-3}}"}}, {"_id": "31588998", "pmid": 31588998, "title": "PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.", "journal": "Cochrane Database Syst Rev", "authors": ["Roncolato F", "Lindemann K", "Willson ML", "Martyn J", "Mileshkin L"], "date": "2019-10-07T00:00:00Z", "doi": "10.1002/14651858.CD012160.pub2", "meta_date_publication": "2019 Oct 7", "meta_volume": "10", "meta_issue": "10", "meta_pages": "CD012160", "score": 50017.594, "text_hl": "We identified five ongoing studies on the effects of PI3K and @GENE_AKT1 @GENE_207 @@@AKT@@@ inhibitors, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and dual @GENE_MTOR @GENE_2475 @@@mTOR@@@ inhibitors.For first-line therapy, an mTOR inhibitor-containing regimen may worsen progression-free survival (HR 1.43, 95% CI 1.06 to 1.93; 1 study, 231 @SPECIES_9606 @@@participants@@@; low-certainty evidence), while for second/third-line therapy, an mTOR inhibitor probably improves progression-free survival compared to chemotherapy or endocrine therapy (HR 0.53, 95% CI 0.31 to 0.91; 1 study, 95 @SPECIES_9606 @@@participants@@@; moderate-certainty evidence). ", "citations": {"NLM": "Roncolato F, Lindemann K, Willson ML, Martyn J, Mileshkin L. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. 2019 Oct 7;10(10):CD012160. PMID: 31588998", "BibTeX": "@article{31588998, title={PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.}, author={Roncolato F and Lindemann K and Willson ML and Martyn J and Mileshkin L}, journal={Cochrane Database Syst Rev}, volume={10}, number={10}, pages={CD012160}}"}}]}